Insider Trading March 16, 2026

Claritev CFO Buys $22,997 of Stock as Company Reports Modest Revenue Gain

Executive purchase coincides with mixed Q4 fiscal 2025 results and a sharp six-month share decline

By Jordan Park CTEV
Claritev CFO Buys $22,997 of Stock as Company Reports Modest Revenue Gain
CTEV

Claritev Corp Executive Vice President and CFO Garis Douglas Michael purchased 1,300 Class A shares on March 16, 2026, for $22,997. The trade comes as the stock trades below the purchase price and after Claritev posted a 6.2% revenue increase for fiscal Q4 2025, alongside operational efficiency improvements and an unchanged buy rating with a reduced price target from Guggenheim.

Key Points

  • Claritev CFO Garis Douglas Michael bought 1,300 Class A shares on March 16, 2026, for $17.69 each, totaling $22,997.
  • Claritev reported fiscal Q4 2025 revenue of $246.6 million, a 6.2% year-over-year increase, and noted operational efficiency improvements.
  • Guggenheim retained a Buy rating on the stock but lowered its price target from $43 to $38, citing margin pressure; the stock has declined about 70% over the past six months.

Transaction details

Garis Douglas Michael, who serves as Executive Vice President and Chief Financial Officer of Claritev Corp (EXCHANGE:CTEV), purchased 1,300 shares of the companys Class A common stock on March 16, 2026, at $17.69 per share. The total value of the acquisition was $22,997. At the time of the report, Claritevs stock was trading at $17.45 and had fallen roughly 70% over the previous six months.

Insider holdings

Following the acquisition, Garis directly holds 206,152 shares of Claritev. Additional indirect holdings reported include 19,927 shares in a Spouses Individual Retirement Account, 45,810 shares in a Reporting Persons Individual Retirement Account, 336 shares in a Daughters Individual Retirement Account, and 345 shares in a Sons Individual Retirement Account.

Company performance and analyst stance

Claritev disclosed fourth-quarter fiscal 2025 results showing revenue of $246.6 million, a 6.2% increase versus the comparable period. The company also reported improvements in operational efficiency. Despite these operational gains, analyst Guggenheim left its rating at Buy but reduced the firms price target on the shares from $43 to $38, attributing the revision to margin pressure.

Investor response to the earnings release was muted, with little movement in the share price noted in the report. The quarterly disclosure also noted sequential growth in claims and indicated favorable pricing and mix stemming from high-cost claims, a set of developments the company presented as reflective of strategic adjustments aimed at strengthening financial results.

Valuation commentary

According to an InvestingPro analysis cited in the report, CTEV appears undervalued at current levels. The write-up noted that additional detail on the assessment is available through the platforms Pro Research Report.

Context for investors

The insider purchase by Claritevs CFO, combined with sequential revenue gains and managements commentary on claims and pricing mix, provides investors with multiple signals to weigh. At the same time, the sizeable six-month decline in the share price and the analyst-driven downward adjustment to the price target underscore the mixed outlook that market participants are processing as the company navigates current market conditions.


Note - The article reports the transaction and company disclosures as presented in the filings and company releases.

Risks

  • Significant recent share-price decline - the stock has fallen approximately 70% over the prior six months, which may reflect elevated market uncertainty for the company (impacts equity markets and investor confidence).
  • Margin pressure noted by Guggenheim - the analyst lowered its price target due to margin concerns, indicating potential financial performance risk (impacts profitability and valuation in the healthcare financials sector).
  • Cautious investor reaction despite positive revenue growth - minimal stock movement following the earnings report suggests investor skepticism or cautious sentiment (impacts market liquidity and investor appetite).

More from Insider Trading

EOG CFO Disposes Stock, Exercises SARs in Transactions Totaling Over $1 Million Mar 16, 2026 AXT Director Disposes $700k in Stock as Company Lowers Q4 Revenue Guidance Mar 16, 2026 Nicolet Bankshares Director Executes Option Exercise, Sells Shares Worth Nearly $496K Mar 16, 2026 AXT CEO Disposes $1.93M in Stock as Company Lowers Q4 Revenue Outlook Mar 16, 2026 AXT CFO Disposes $4.5 Million in Stock as Guidance Is Trimmed Mar 16, 2026